Pills on a US dollar bill

Megafinanzas para la investigación de medicamentos

SEATTLE – Mientras las subas abusivas de precios por un puñado de farmacéuticas ocupan los titulares, un aspecto preocupante de esta historia ha quedado minimizado. Los exorbitantes aumentos de los precios de los medicamentos existentes –genéricos incluidos– no solo están motivados por la especulación extrema, sino también por un profundo escepticismo sobre la factibilidad económica del desarrollo de nuevos medicamentos. Y ese escepticismo está justificado.

Los modelos tradicionales para el financiamiento del desarrollo de drogas tambalean. En EE. UU. y muchos otros países desarrollados, el costo promedio de llevar un medicamento al mercado se ha disparado, aun cuando las patentes de algunos de los medicamentos más rentables del sector ya han expirado. El capital de riesgo se ha retirado de las empresas dedicadas a las primeras etapas de las ciencias de la vida y las grandes empresas farmacéuticas ven que menos drogas llegan al mercado por dólar gastado en investigación y desarrollo.

De hecho –en promedio– solo 1 de cada 10 000 compuestos identificados como potencialmente útiles en las primeras etapas del desarrollo logra finalmente ser aprobado por los reguladores. El proceso de aprobación puede demorar hasta 15 años y, de equivocarse, prefiere hacerlo por exceso de precaución. Incluso entre los medicamentos que llegan a la instancia de las pruebas clínicas en humanos, solo uno de cada cinco logra superarlas.

To continue reading, please log in or enter your email address.

Registration is quick and easy and requires only your email address. If you already have an account with us, please log in. Or subscribe now for unlimited access.


Log in

  1. Patrick Kovarik/Getty Images

    The Summit of Climate Hopes

    Presidents, prime ministers, and policymakers gather in Paris today for the One Planet Summit. But with no senior US representative attending, is the 2015 Paris climate agreement still viable?

  2. Trump greets his supporters The Washington Post/Getty Images

    Populist Plutocracy and the Future of America

    • In the first year of his presidency, Donald Trump has consistently sold out the blue-collar, socially conservative whites who brought him to power, while pursuing policies to enrich his fellow plutocrats. 

    • Sooner or later, Trump's core supporters will wake up to this fact, so it is worth asking how far he might go to keep them on his side.
  3. Agents are bidding on at the auction of Leonardo da Vinci's 'Salvator Mundi' Eduardo Munoz Alvarez/Getty Images

    The Man Who Didn’t Save the World

    A Saudi prince has been revealed to be the buyer of Leonardo da Vinci's "Salvator Mundi," for which he spent $450.3 million. Had he given the money to the poor, as the subject of the painting instructed another rich man, he could have restored eyesight to nine million people, or enabled 13 million families to grow 50% more food.

  4.  An inside view of the 'AknRobotics' Anadolu Agency/Getty Images

    Two Myths About Automation

    While many people believe that technological progress and job destruction are accelerating dramatically, there is no evidence of either trend. In reality, total factor productivity, the best summary measure of the pace of technical change, has been stagnating since 2005 in the US and across the advanced-country world.

  5. A student shows a combo pictures of three dictators, Austrian born Hitler, Castro and Stalin with Viktor Orban Attila Kisbenedek/Getty Images

    The Hungarian Government’s Failed Campaign of Lies

    The Hungarian government has released the results of its "national consultation" on what it calls the "Soros Plan" to flood the country with Muslim migrants and refugees. But no such plan exists, only a taxpayer-funded propaganda campaign to help a corrupt administration deflect attention from its failure to fulfill Hungarians’ aspirations.

  6. Project Syndicate

    DEBATE: Should the Eurozone Impose Fiscal Union?

    French President Emmanuel Macron wants European leaders to appoint a eurozone finance minister as a way to ensure the single currency's long-term viability. But would it work, and, more fundamentally, is it necessary?

  7. The Year Ahead 2018

    The world’s leading thinkers and policymakers examine what’s come apart in the past year, and anticipate what will define the year ahead.

    Order now